Inhibikase Therapeutics (IKT) Invested Capital (2020 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Invested Capital for 6 consecutive years, with $72.9 million as the latest value for Q3 2025.
- Quarterly Invested Capital rose 19015.9% to $72.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $72.9 million through Sep 2025, up 19015.9% year-over-year, with the annual reading at $95.0 million for FY2024, 736.08% up from the prior year.
- Invested Capital for Q3 2025 was $72.9 million at Inhibikase Therapeutics, down from $80.1 million in the prior quarter.
- The five-year high for Invested Capital was $95.0 million in Q4 2024, with the low at -$385381.0 in Q3 2024.
- Average Invested Capital over 5 years is $34.9 million, with a median of $25.4 million recorded in 2023.
- The sharpest move saw Invested Capital plummeted 102.54% in 2024, then skyrocketed 19015.9% in 2025.
- Over 5 years, Invested Capital stood at $38.4 million in 2021, then plummeted by 44.86% to $21.2 million in 2022, then crashed by 46.37% to $11.4 million in 2023, then skyrocketed by 736.08% to $95.0 million in 2024, then decreased by 23.25% to $72.9 million in 2025.
- According to Business Quant data, Invested Capital over the past three periods came in at $72.9 million, $80.1 million, and $85.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.